Ghent University Academic Bibliography

Advanced

Melanocyte-specific immune response in a patient with multiple regressing nevi and a history of melanoma

Reinhart Speeckaert, Nanja van Geel UGent, Rosalie M Luiten, Mireille Van Gele UGent, Marijn Speeckaert UGent, Jo Lambert UGent, Karim Vermaelen UGent, Esther PM Tjin and Lieve Brochez UGent (2011) ANTICANCER RESEARCH. 31(11). p.3697-3703
abstract
Background/Aim: Regressing nevi are considered an example of an efficient early antitumoral response preventing the development of neoplasia. The underlying mechanism has not been elucidated, although an immune-based destruction of melanocytes is supposed. The aim of this study was to provide evidence of an effective immunosurveillance of pigment lesions in a patient at high risk of melanoma. Case Report: A patient with the dysplastic nevus syndrome and a history of melanoma was included in this study. Since 2003, a marked regression of almost all nevi was observed. Immunohistochemistry was performed and the antigen specificity of T-cells was analyzed on T-cells isolated from a regressing nevus by flow cytometry using HLA-A2-peptide tetramers containing Mart-1(26-35), gp100(280-288), gp100(209-217) and tyrosinase(369-377). Immunohistochemistry of the regressing nevi showed a strong infiltrate of CD4 + and CD8 + T-cells. Flow cytometric analyses demonstrated the presence of a CD8 + T-cell response against gp100(280-288) and Mart-1(26-35) both in peripheral blood and in a regressing nevus. Conclusion: These findings indicate that an immune reaction against melanocyte differentiation antigens can target specifically nevi without signs of vitiligo and suggests that boosting the anti-melanocyte immune response in patients at high risk for melanoma may prevent tumor development at an early stage.
Please use this url to cite or link to this publication:
author
organization
year
type
journalArticle (original)
publication status
published
subject
keyword
immune resonse, regression., Dysplastic nevi, melanoma, melanocyte
journal title
ANTICANCER RESEARCH
Anticancer Res.
volume
31
issue
11
pages
3697 - 3703
Web of Science type
Article
Web of Science id
000297482000007
JCR category
ONCOLOGY
JCR impact factor
1.725 (2011)
JCR rank
134/190 (2011)
JCR quartile
3 (2011)
ISSN
0250-7005
language
English
UGent publication?
yes
classification
A1
copyright statement
I have transferred the copyright for this publication to the publisher
id
1956302
handle
http://hdl.handle.net/1854/LU-1956302
alternative location
http://ar.iiarjournals.org/content/31/11/3697.abstract
date created
2011-11-30 08:43:34
date last changed
2016-12-19 15:42:20
@article{1956302,
  abstract     = {Background/Aim: Regressing nevi are considered an example of an efficient early antitumoral response preventing the development of neoplasia. The underlying mechanism has not been elucidated, although an immune-based destruction of melanocytes is supposed. The aim of this study was to provide evidence of an effective immunosurveillance of pigment lesions in a patient at high risk of melanoma.
Case Report: A patient with the dysplastic nevus syndrome and a history of melanoma was included in this study. Since 2003, a marked regression of almost all nevi was observed. Immunohistochemistry was performed and the antigen specificity of T-cells was analyzed on T-cells isolated from a regressing nevus by flow cytometry using HLA-A2-peptide tetramers containing Mart-1(26-35), gp100(280-288), gp100(209-217) and tyrosinase(369-377). Immunohistochemistry of the regressing nevi showed a strong infiltrate of CD4 + and CD8 + T-cells. Flow cytometric analyses demonstrated the presence of a CD8 + T-cell response against gp100(280-288) and Mart-1(26-35) both in peripheral blood and in a regressing nevus.
Conclusion: These findings indicate that an immune reaction against melanocyte differentiation antigens can target specifically nevi without signs of vitiligo and suggests that boosting the anti-melanocyte immune response in patients at high risk for melanoma may prevent tumor development at an early stage.},
  author       = {Speeckaert, Reinhart and van Geel, Nanja and Luiten, Rosalie M and Van Gele, Mireille and Speeckaert, Marijn and Lambert, Jo and Vermaelen, Karim and Tjin, Esther PM and Brochez, Lieve},
  issn         = {0250-7005},
  journal      = {ANTICANCER RESEARCH},
  keyword      = {immune resonse,regression.,Dysplastic nevi,melanoma,melanocyte},
  language     = {eng},
  number       = {11},
  pages        = {3697--3703},
  title        = {Melanocyte-specific immune response in a patient with multiple regressing nevi and a history of melanoma},
  url          = {http://ar.iiarjournals.org/content/31/11/3697.abstract},
  volume       = {31},
  year         = {2011},
}

Chicago
Speeckaert, Reinhart, Nanja van Geel, Rosalie M Luiten, Mireille Van Gele, Marijn Speeckaert, Jo Lambert, Karim Vermaelen, Esther PM Tjin, and Lieve Brochez. 2011. “Melanocyte-specific Immune Response in a Patient with Multiple Regressing Nevi and a History of Melanoma.” Anticancer Research 31 (11): 3697–3703.
APA
Speeckaert, R., van Geel, N., Luiten, R. M., Van Gele, M., Speeckaert, M., Lambert, J., Vermaelen, K., et al. (2011). Melanocyte-specific immune response in a patient with multiple regressing nevi and a history of melanoma. ANTICANCER RESEARCH, 31(11), 3697–3703.
Vancouver
1.
Speeckaert R, van Geel N, Luiten RM, Van Gele M, Speeckaert M, Lambert J, et al. Melanocyte-specific immune response in a patient with multiple regressing nevi and a history of melanoma. ANTICANCER RESEARCH. 2011;31(11):3697–703.
MLA
Speeckaert, Reinhart, Nanja van Geel, Rosalie M Luiten, et al. “Melanocyte-specific Immune Response in a Patient with Multiple Regressing Nevi and a History of Melanoma.” ANTICANCER RESEARCH 31.11 (2011): 3697–3703. Print.